SELLAS Life Sciences (SLS) Acquisitions (2013 - 2014)

SELLAS Life Sciences' (SLS) quarterly Acquisitions came in at $100000.0 in Q4 2014, down 67.21% on a QoQ basis from $305000.0 in Q2 2014.

SELLAS Life Sciences (SLS) Acquisitions (2013 - 2014) Analysis & Trends

SELLAS Life Sciences (SLS) has 2 years of Acquisitions data on file, last reported at $100000.0 in Q4 2014.

On a quarterly basis, Acquisitions changed N/A year-over-year to $100000.0 in Q4 2014; TTM through Sep 2015 was $100000.0, a 95.68% decrease from a year earlier, with the FY2017 full-year figure at $12.2 million, changed N/A from the prior year.
Acquisitions for Q4 2014 stood at $100000.0, down from $305000.0 in the prior quarter.
Over the last five years, Acquisitions for SLS reached as high as $10.1 million in Q1 2013 and fell as low as $100000.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	SELLAS Life Sciences	3.23 Mn	3.23 Mn	-	-

Download Data